bydureon.eu Report : Visit Site


  • Server:astrazeneca.com Comm...

    The main IP address: 165.160.13.20,Your server United States,Wilmington ISP:Corporation Service Company  TLD:eu CountryCode:US

    The description :for healthcare professionals only - the astrazeneca medicines portal provides information on astrazeneca products....

    This report updates in 19-Aug-2018

Technical data of the bydureon.eu


Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host bydureon.eu. Currently, hosted in United States and its service provider is Corporation Service Company .

Latitude: 39.735778808594
Longitude: -75.665702819824
Country: United States (US)
City: Wilmington
Region: Delaware
ISP: Corporation Service Company

the related websites

HTTP Header Analysis


HTTP Header information is a part of HTTP protocol that a user's browser sends to called astrazeneca.com Communique/4.2.0 containing the details of what the browser wants and will accept back from the web server.

Via:1.1 4ee3d5920fafcf4bca394fd489654c8c.cloudfront.net (CloudFront)
X-Cache:Miss from cloudfront
X-Content-Type-Options:nosniff
Content-Encoding:gzip
Transfer-Encoding:chunked
Set-Cookie:AWSELB=4953BDA51AF1DB46D6871F2A5DC9A4DDC456FA9363D61408B55723B131333AB4D8580F81D5D649367647A95A8E245A6AA369C810D648AC0756A46CA5EB744145CC94904BB8;PATH=/;MAX-AGE=900
Vary:Accept-Encoding,User-Agent
Server:astrazeneca.com Communique/4.2.0
Connection:keep-alive
X-Amz-Cf-Id:1o30-ARiYaE1-nccmG0GoYpGHQ3ZDVRUk4F1N2R2tl0IdCEPLkyrHQ==
Cache-Control:max-age=0, no-cache, s-maxage=10, no-cache="set-cookie"
Date:Sat, 18 Aug 2018 17:16:26 GMT
X-Frame-Options:SAMEORIGIN
Content-Type:text/html; charset=UTF-8
X-Mod-Pagespeed:Powered by Open Digital Customer Support

DNS

soa:dns1.cscdns.net. hostmaster.cscdns.net. 2013032507 28800 7200 604800 14400
ns:dns1.cscdns.net.
dns2.cscdns.net.
ipv4:IP:165.160.13.20
ASN:19574
OWNER:CSC - Corporation Service Company, US
Country:US
IP:165.160.15.20
ASN:19574
OWNER:CSC - Corporation Service Company, US
Country:US
mx:MX preference = 10, mail exchanger = custmx.cscdns.net.

HtmlToText

-- -- -- -- toggle navigation medicines medicines my account logout home cardiovascular cardiovascular brilique (ticagrelor) brilique (ticagrelor) product information product information indications prescribing brilique 90mg brilique 90mg odt prescribing brilique 60mg administration warnings and precautions other adverse events guidelines clinical studies mode of action mode of action brilique is not a thienopyridine brilique works via a dual pathway resources references home hot topics expert opinion publication alerts publication alerts coming soon meeting calendar useful links diabetes diabetes forxiga® (dapagliflozin) forxiga® (dapagliflozin) indications and dosing treatment with forxiga(dapagliflozin) clinical trial data clinical trial data clinical trial data - hba1c weight blood pressure real world evidence real world evidence hba1c weight blood pressure pooled data safety and tolerability forxiga (dapagliflozin) vs saxagliptin (a dpp4 inhibitor) forxiga (dapagliflozin) in combination with glp or insulin forxiga (dapagliflozin) in combination with glp or insulin hba1c weight study details clinical considerations resources references onglyza (saxagliptin) onglyza (saxagliptin) therapeutic indications control across a range of clinical settings control across a range of clinical settings dual therapy: add-on to metformin renal impairment vs placebo onglyza vs su* outcomes beyond glycaemic control savor: the onglyza cv outcomes study savor: the onglyza cv outcomes study cardiovascular risk: baseline characteristics baseline characteristics savor: primary composite endpoint savor: secondary composite endpoint in the real world safety profile clinical considerations once daily convenience why choose onglyza? qtern (saxagliptin / dapagliflozin) qtern (saxagliptin / dapagliflozin) therapeutic indications and posology therapeutic indications and posology indications posology qtern™ is for patients on metformin and forxiga® (dapagliflozin) who require additional hba1c reduction. mode of action efficacy safety & tolerability dosing & cost qtern™: clinical considerations qtern™ summary references fixing dad oncology oncology lynparza ▼ (olaparib) lynparza ▼ (olaparib) prescribing information prescribing information indications & usage dosing and administration dose adjustments safety & tolerability warnings & precautions unmet need in ovarian cancer about lynparza about lynparza mechanism of action about study 19 about study 19 brcam sub-analysis patient characteristics efficacy tfst tsst overall survival (os) quality of life (qol) study overview about brca testing about brca testing brca testing references tagrisso ▼ (osimertinib) tagrisso ▼ (osimertinib) prescribing information prescribing information dosing tolerability testing for the t790m mutation about the t790m mutation about the t790m mutation tagrisso is specifically designed to target the egfr t790m mutation[1] mechanism of action (moa) clinical trials clinical trials efficacy references zoladex (goserelin) zoladex (goserelin) prescribing information prescribing information indications & usage administration importance of brca testing types of brca gene mutation about tumour brca testing tumour brca testing service tumour brca testing service who is eligible for this service? how to access the service testing process downloadable testing forms references respiratory respiratory symbicort copd (budesonide/formoterol) symbicort copd (budesonide/formoterol) product information product information indication copd: ics/labas and symbicort copd: ics/labas and symbicort efficacy capacity of daily living device choice (turbohaler vs pmdi) tolerability summary of efficacy and device choice case study how to use symbicort devices in copd how to use symbicort devices in copd how to use the turbohaler how to use the pmdi about copd copd guidelines cost references symbicort asthma (budesonide/formoterol) symbicort asthma (budesonide/formoterol) product information product information indication presentation device asthma ics/labas and symbicort asthma ics/labas and symbicort goals of treatment window of opportunity exacerbation reduction symptom control tolerability summary of symbicort efficacy case studies mode of action turbohaler device turbohaler device how to use device how to use the symbicort turbohaler about asthma asthma guidelines cost references fasenra ▼(benralizumab) fasenra ▼(benralizumab) indication mode of action study design efficacy safety dosing references supply chain supply chain supply of astrazeneca medicines supply requirements form our medicines supply of medicines astrazeneca customers contact supply chain faq more hide welcome to astrazeneca medicines whether you need to cross-check an indication, help a patient understand their condition, or catch up on a recent meeting, you'll find the right information fast, letting you return to your number one priority: helping your patients. astrazeneca medicines is an online resource for healthcare professionals. medicines resources clinical trials contact astrazeneca cardiovascular cardiovascular brilique (ticagrelor) prescribing information diabetes diabetes bydureon (exenatide) prescribing information forxiga (dapagliflozin) prescribing information onglyza (saxagliptin) prescribing information qtern (saxagliptin/dapagliflozin) prescribing information oncology oncology faslodex (fulvestrant) prescribing information iressa (gefitinib) prescribing information lynparza▼ (olaparib) prescribing information tagrisso▼ (osimertinib) prescribing information zoladex (goserelin) prescribing information respiratory respiratory daxas▼ (roflumilast) prescribing information duaklir▼ (aclidinium/formoterol fumarate dehydrate) prescribing information fasenra▼ (benralizumab) prescribing information symbicort asthma (budesonide/formoterol) prescribing information symbicort copd (budesonide/formoterol) prescribing information gb-12085 - may 2018 close filters add filters arrange by most recent most recent oldest most popular least popular a to z z to a filter by therapeutic areas therapeutic areas medicines medicines disease state disease state audience audience -- load more brilique (ticagrelor) prescribing information bydureon (exenatide) prescribing information daxas▼(roflumilast) prescribing information duaklir genuair ▼ (aclidinium/formoterol fumarate dehydrate) prescribing information fasenra ▼ (benralizumab) prescribing information faslodex (fulvestrant) prescribing information forxiga (dapagliflozin) prescribing information iressa (gefitinib) prescribing information lynparza ▼ (olaparib) prescribing information onglyza (saxagliptin) prescribing information qtern (saxagliptin / dapagliflozin) prescribing information symbicort (budesonide/formoterol) asthma prescribing information symbicort (budesonide/formoterol) copd prescribing information tagrisso ▼ (osimertinib) prescribing information zoladex (goserelin) prescribing information astrazeneca are committed to meeting patient needs through innovative medicines and clinical excellence, we conduct clinical trials to help determine the safety and efficacy of a new medicine. in line with our group corporate responsibility policy on transparency, we are committed to open communication of information on astrazeneca's clinical trials. we provide details of new and ongoing clinical trials sponsored by astrazeneca. visit the astrazeneca clinical trials website at astrazenecaclinicaltrials.com . for medical enquiries about our products (including questions on how to take our medicines, to report a side effect or make a complaint regarding one of our medicines). uk based medical information team call: 0800 783 0033. lines are open from monday-friday, 9am - 5pm. outside these hours and on bank holidays, an out of hours service is available to assist with urgent enquiries. exit ramp component section begins exit ramp component section ends -- welcome to the astrazeneca medicines site s

URL analysis for bydureon.eu


https://medicines.astrazeneca.co.uk/bin/downloadlink?downloadpath=/content/dam/multibrand/uk/en/prescribinginformation/faslodex_uk.pdf
https://medicines.astrazeneca.co.uk/home/oncology/zoladex/prescribing-information/indications-usage.html#indications-usage
https://medicines.astrazeneca.co.uk/home/oncology/tagrisso/about-t790m-mutation.html
https://medicines.astrazeneca.co.uk/home/respiratory/symbicort-asthma/prescribing_information/indication.html#indication
https://medicines.astrazeneca.co.uk/home/diabetes/forxiga/pooled-data.html
https://medicines.astrazeneca.co.uk/home/diabetes/onglyza/significant-improvements.html#significant-improvements
https://medicines.astrazeneca.co.uk/home/oncology/zoladex.html
https://medicines.astrazeneca.co.uk/bin/downloadlink?downloadpath=/content/dam/multibrand/uk/en/prescribinginformation/brilique-pi.pdf
https://medicines.astrazeneca.co.uk/home/diabetes/forxiga/clinical-trial-data/hba1c0.html#hba1c0
https://medicines.astrazeneca.co.uk/home/oncology/tbrca-testing/about.html
https://medicines.astrazeneca.co.uk/home/cookie-policy.html
https://medicines.astrazeneca.co.uk/home/supply-of-astrazeneca-medicines/supply-of-medicines.html
https://medicines.astrazeneca.co.uk/home/oncology/tagrisso/prescribing-information/tolerability.html#tolerability
https://medicines.astrazeneca.co.uk/home/cardiovascular/brilique/product-information.html
https://medicines.astrazeneca.co.uk/home/respiratory/symbicort-asthma/calculator.html
yellowcard.mhra.gov.uk
astrazeneca.co.uk

Whois Information


Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

% The WHOIS service offered by EURid and the access to the records
% in the EURid WHOIS database are provided for information purposes
% only. It allows persons to check whether a specific domain name
% is still available or not and to obtain information related to
% the registration records of existing domain names.
%
% EURid cannot, under any circumstances, be held liable in case the
% stored information would prove to be wrong, incomplete or not
% accurate in any sense.
%
% By submitting a query you agree not to use the information made
% available to:
%
% - allow, enable or otherwise support the transmission of unsolicited,
% commercial advertising or other solicitations whether via email or
% otherwise;
% - target advertising in any possible way;
%
% - to cause nuisance in any possible way to the registrants by sending
% (whether by automated, electronic processes capable of enabling
% high volumes or other possible means) messages to them.
%
% Without prejudice to the above, it is explicitly forbidden to extract,
% copy and/or use or re-utilise in any form and by any means
% (electronically or not) the whole or a quantitatively or qualitatively
% substantial part of the contents of the WHOIS database without prior
% and explicit permission by EURid, nor in any attempt hereof, to apply
% automated, electronic processes to EURid (or its systems).
%
% You agree that any reproduction and/or transmission of data for
% commercial purposes will always be considered as the extraction of a
% substantial part of the content of the WHOIS database.
%
% By submitting the query you agree to abide by this policy and accept
% that EURid can take measures to limit the use of its WHOIS services
% in order to protect the privacy of its registrants or the integrity
% of the database.
%
% The EURid WHOIS service on port 43 (textual whois) never
% discloses any information concerning the registrant.
% Registrant and onsite contact information can be obtained through use of the
% webbased whois service available from the EURid website www.eurid.eu
%
% WHOIS bydureon.eu
Domain: bydureon.eu

Registrant:
NOT DISCLOSED!
Visit www.eurid.eu for webbased whois.

Onsite(s):
NOT DISCLOSED!
Visit www.eurid.eu for webbased whois.

Technical:
Name: DNS Administrator
Organisation: CSC Corporate Domains, Inc.
Language: en
Phone: +1.3026365400
Fax: +1.3026365454
Email: [email protected]

Registrar:
Name: Corporation Service Company
Website: https://www.cscdigitalbrand.services/

Name servers:
dns1.cscdns.net
dns2.cscdns.net

Please visit www.eurid.eu for more info.

  REFERRER http://www.eurid.eu

  REGISTRAR EURID

SERVERS

  SERVER eu.whois-servers.net

  ARGS bydureon.eu

  PORT 43

  TYPE domain

DOMAIN

  NAME bydureon.eu

REGISTRAR

  NAME Corporation Service Company

  URL https://www.cscdigitalbrand.services/

NSERVER

  DNS1.CSCDNS.NET 209.112.114.33

  DNS2.CSCDNS.NET 69.36.145.33

OWNER
NOT DISCLOSED!
Visit www.eurid.eu for webbased whois.
Onsite(s):
NOT DISCLOSED!
Visit www.eurid.eu for webbased whois.
Technical:
Name: DNS Administrator
Organisation: CSC Corporate Domains, Inc.
Language: en
Phone: +1.3026365400
Fax: +1.3026365454
Email: [email protected]

  REGISTERED yes

Go to top

Mistakes


The following list shows you to spelling mistakes possible of the internet users for the website searched .

  • www.ubydureon.com
  • www.7bydureon.com
  • www.hbydureon.com
  • www.kbydureon.com
  • www.jbydureon.com
  • www.ibydureon.com
  • www.8bydureon.com
  • www.ybydureon.com
  • www.bydureonebc.com
  • www.bydureonebc.com
  • www.bydureon3bc.com
  • www.bydureonwbc.com
  • www.bydureonsbc.com
  • www.bydureon#bc.com
  • www.bydureondbc.com
  • www.bydureonfbc.com
  • www.bydureon&bc.com
  • www.bydureonrbc.com
  • www.urlw4ebc.com
  • www.bydureon4bc.com
  • www.bydureonc.com
  • www.bydureonbc.com
  • www.bydureonvc.com
  • www.bydureonvbc.com
  • www.bydureonvc.com
  • www.bydureon c.com
  • www.bydureon bc.com
  • www.bydureon c.com
  • www.bydureongc.com
  • www.bydureongbc.com
  • www.bydureongc.com
  • www.bydureonjc.com
  • www.bydureonjbc.com
  • www.bydureonjc.com
  • www.bydureonnc.com
  • www.bydureonnbc.com
  • www.bydureonnc.com
  • www.bydureonhc.com
  • www.bydureonhbc.com
  • www.bydureonhc.com
  • www.bydureon.com
  • www.bydureonc.com
  • www.bydureonx.com
  • www.bydureonxc.com
  • www.bydureonx.com
  • www.bydureonf.com
  • www.bydureonfc.com
  • www.bydureonf.com
  • www.bydureonv.com
  • www.bydureonvc.com
  • www.bydureonv.com
  • www.bydureond.com
  • www.bydureondc.com
  • www.bydureond.com
  • www.bydureoncb.com
  • www.bydureoncom
  • www.bydureon..com
  • www.bydureon/com
  • www.bydureon/.com
  • www.bydureon./com
  • www.bydureonncom
  • www.bydureonn.com
  • www.bydureon.ncom
  • www.bydureon;com
  • www.bydureon;.com
  • www.bydureon.;com
  • www.bydureonlcom
  • www.bydureonl.com
  • www.bydureon.lcom
  • www.bydureon com
  • www.bydureon .com
  • www.bydureon. com
  • www.bydureon,com
  • www.bydureon,.com
  • www.bydureon.,com
  • www.bydureonmcom
  • www.bydureonm.com
  • www.bydureon.mcom
  • www.bydureon.ccom
  • www.bydureon.om
  • www.bydureon.ccom
  • www.bydureon.xom
  • www.bydureon.xcom
  • www.bydureon.cxom
  • www.bydureon.fom
  • www.bydureon.fcom
  • www.bydureon.cfom
  • www.bydureon.vom
  • www.bydureon.vcom
  • www.bydureon.cvom
  • www.bydureon.dom
  • www.bydureon.dcom
  • www.bydureon.cdom
  • www.bydureonc.om
  • www.bydureon.cm
  • www.bydureon.coom
  • www.bydureon.cpm
  • www.bydureon.cpom
  • www.bydureon.copm
  • www.bydureon.cim
  • www.bydureon.ciom
  • www.bydureon.coim
  • www.bydureon.ckm
  • www.bydureon.ckom
  • www.bydureon.cokm
  • www.bydureon.clm
  • www.bydureon.clom
  • www.bydureon.colm
  • www.bydureon.c0m
  • www.bydureon.c0om
  • www.bydureon.co0m
  • www.bydureon.c:m
  • www.bydureon.c:om
  • www.bydureon.co:m
  • www.bydureon.c9m
  • www.bydureon.c9om
  • www.bydureon.co9m
  • www.bydureon.ocm
  • www.bydureon.co
  • bydureon.eum
  • www.bydureon.con
  • www.bydureon.conm
  • bydureon.eun
  • www.bydureon.col
  • www.bydureon.colm
  • bydureon.eul
  • www.bydureon.co
  • www.bydureon.co m
  • bydureon.eu
  • www.bydureon.cok
  • www.bydureon.cokm
  • bydureon.euk
  • www.bydureon.co,
  • www.bydureon.co,m
  • bydureon.eu,
  • www.bydureon.coj
  • www.bydureon.cojm
  • bydureon.euj
  • www.bydureon.cmo
Show All Mistakes Hide All Mistakes